09:51 AM EST - Satellos Bioscience Inc. : Announced today that the first participant with Duchenne muscular dystrophy has been dosed in the Phase 1b safety and pharmacokinetics trial in DMD patients. Satellos Bioscience Inc.
shares T.MSCL are trading unchanged at $1.00.
